sickle-cell disease
Enable an agent to recognise sickle-cell disease, represent its genotype and evolving manifestations, and identify care actions that require clinical review.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
recalled by Codex without web access - no source was read
Researched by: Codex
Purpose and description
Enable an agent to recognise sickle-cell disease, represent its genotype and evolving manifestations, and identify care actions that require clinical review.
Sickle-cell disease is a group of inherited haemoglobin disorders in which haemoglobin S, produced by an HBB variant and inherited with another disease-causing HBB allele, causes red-cell sickling, chronic haemolysis and vaso-occlusion with variable multisystem complications.
It can be Check whether diagnostic evidence supports sickle-cell disease and the asserted subtype.; Distinguish inherited disease identity from current activity, acute complications and residual injury.; Compare laboratory and symptom trajectories with the individual's baseline and treatment context.; Flag reported features for urgent clinician assessment using an identified, applicable clinical protocol.; Identify missing surveillance, prevention or treatment-review evidence against a versioned guideline.; Summarise burden and treatment response while exposing uncertain attribution and incomplete observation..
Distinguishing features
The disease group includes HbSS, HbSC and HbS/beta-thalassaemia; identifying haemoglobin S alone does not establish which disease subtype is present.
Sickle-cell trait typically involves one HbS allele and one normal beta-globin allele and must not be equated with sickle-cell disease.
Sickle-cell anaemia commonly denotes HbSS, with some conventions also including HbS/beta-zero-thalassaemia; the model must record the convention rather than treat that term as universally synonymous with the whole disease group.
Anaemia, pain or sickled cells on a blood film alone do not establish the disease; haemoglobin analysis and, where needed, molecular evidence must support classification.
The inherited disease persists between acute events; a pain episode or acute chest syndrome is a manifestation, not a replacement identity for the underlying condition.
Scope
+ Disease identity and clinically meaningful haemoglobin genotype
+ Diagnostic evidence, uncertainty and versioned terminology mappings
+ Sickling, haemolysis and vaso-occlusive disease activity
+ Acute complications, longitudinal course and cumulative organ injury
+ Prevention, disease-modifying treatment and response assessment
+ Population and care-access context needed to interpret disease burden
- The patient's complete demographic and medical record
- Sickle-cell trait as an independent carrier-state model
- Other haemoglobin disorders except where needed for differential diagnosis or compound genotypes
- Individual visits, admissions and billing transactions
- Laboratory instruments, assay procedures and specimen logistics
- Independent models of medicines, transplantation procedures and gene-therapy products
Characteristics
- Haemoglobin genotype
- HbSS, HbSC, HbS/beta-zero-thalassaemia, HbS/beta-plus-thalassaemia, other specified sickling genotype, unresolved Separates disease subtypes and informs interpretation of expected manifestations without assuming an individual's severity.
- Diagnostic assertion status
- Screen-positive, suspected, confirmed, disputed, reclassified; with evidence and date Prevents a screening result or provisional code from becoming an unsupported confirmed diagnosis.
- Haemoglobin fractions
- HbS, HbF, HbA and HbA2 as percentages, with assay, date and treatment context Supports subtype interpretation and treatment monitoring; transfusion and treatment can alter the observed pattern.
- Haemoglobin concentration relative to baseline
- g/dL, with usual range for the individual, sampling date and recent transfusion history Distinguishes chronic anaemia from an acute fall requiring assessment.
- Haemolysis evidence
- Reticulocyte count, bilirubin and lactate dehydrogenase, each with units, reference interval and date Characterises haemolytic activity while preserving the limitations of nonspecific markers.
- Vaso-occlusive pain burden
- Episodes and pain days per stated observation period, distinguishing home-managed and healthcare-attended events Captures burden that admission counts alone can miss.
- Current complication status
- Absent, suspected, confirmed, resolving or historical for each named complication Separates acute clinical concerns from established history and chronic injury.
- Organ involvement
- Organ-specific findings, functional measurements, assessment dates and uncertainty Represents cumulative injury without imposing a single universal disease stage.
- Treatment exposure and response
- Links to preventive care, disease-modifying medicines, transfusion programmes, transplantation or gene therapy and their observed outcomes Makes disease measurements interpretable in the context of interventions.
- Terminology mapping
- Code, label, coding system, release or national modification, mapping scope and verification source Prevents broad disease codes from being mistaken for genotype-specific or complication-specific assertions.
Also called
Where this came from
wikidata · CC0 1.0
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 6 bundles · 11 layers · 18 findings · 30 questions.
Identity and diagnostic evidence Establishes which sickling disorder is represented and how confidently it has been identified.
Trait, disease subtypes and terminology labels can be confused, especially when laboratory patterns have been altered by treatment.
Genotype and disease boundary
Separates the disease group, its subtypes and neighbouring carrier states.
Subtype supported by evidence
Record the asserted genotype, supporting evidence and meaning of any narrower label such as sickle-cell anaemia.
- Which haemoglobin genotype is asserted, and what evidence distinguishes it from sickle-cell trait or another haemoglobin disorder? definition
- Does the recorded term denote the whole disease group or a specified subtype under the source's terminology convention? boundary
Confirmation and code provenance
Preserves the origin and limitations of diagnostic assertions and terminology mappings.
Interpretable diagnostic record
Distinguish screening from confirmation and retain assay, age, treatment and coding context.
- Which screening, haemoglobin-analysis or molecular results support confirmation, and could age, recent transfusion or prior treatment affect their interpretation? provenance
- Which issuing body's diagnostic guidance and which ICD or SNOMED CT release support the assertion and its mapping? provenance
Sickling and haemolytic state Represents the biological processes and measurements underlying current disease expression.
Genotype alone cannot describe current anaemia, haemolysis or the effects of haemoglobin composition and treatment.
Haemoglobin composition
Connects HbS-related sickling with measured haemoglobin fractions and their modifiers.
Haemoglobin fraction context
Record haemoglobin fractions as contextual observations rather than a standalone severity score.
- What are the measured HbS, HbF, HbA and HbA2 fractions, and when and by which method were they measured? measurement
- Which genotype, age-related factors, transfusions or disease-modifying treatments are needed to interpret those fractions? boundary
Anaemia and haemolysis
Distinguishes baseline haemolytic anaemia from an acute change or an additional cause.
Baseline and acute deviation
Interpret haemoglobin and haemolysis measurements against the individual's established baseline.
- How do haemoglobin concentration, reticulocytes and haemolysis markers compare with the individual's baseline? measurement
- Does an acute change require clinical evaluation for possibilities such as sequestration, marrow suppression, bleeding or a transfusion-related reaction? action
Vaso-occlusion and acute complications Represents acute manifestations, their evidence and the need for timely clinical assessment.
Pain events and other acute complications differ in definition, urgency and evidential requirements.
Pain events and daily burden
Separates acute vaso-occlusive pain from persistent pain and alternative causes.
Pain phenotype and observation
Capture episode characteristics and burden across home and healthcare settings.
- What evidence supports attribution of this pain to an acute vaso-occlusive event, persistent pain or another cause? boundary
- How many pain days and discrete episodes occurred in the stated period, and which were managed outside healthcare facilities? measurement
Time-critical complications
Tracks suspected or confirmed acute chest syndrome, stroke, serious infection, sequestration and priapism.
Complication evidence and escalation
Keep symptoms, diagnostic status and protocol-based escalation distinct.
- Which symptoms, examination findings, imaging or laboratory evidence support each suspected complication, and when did they begin? provenance
- What urgent assessment or escalation does the applicable clinical protocol require, and has that action been documented? action
Longitudinal injury and lived burden Represents cumulative organ effects, function and variation across the life course.
Low recent acute-event frequency does not establish low cumulative injury or low daily burden.
Organ-specific course
Tracks cerebral, renal, retinal, cardiopulmonary, splenic and musculoskeletal involvement.
Organ injury and surveillance
Record organ-specific evidence and applicable surveillance without inventing a universal staging system.
- Which organ abnormalities are established, what supports their attribution to sickle-cell disease, and how have they changed? measurement
- Which surveillance assessments are indicated by the cited guidance for this age, genotype and clinical history? action
Function and population context
Connects daily burden and access to care with appropriately bounded population evidence.
Burden with observation context
Represent fatigue, participation and care barriers without treating healthcare utilisation as a complete severity measure.
- What fatigue, mobility, school, work or daily-activity limitations are reported, using which instrument and observation period? measurement
- For any prevalence or outcome estimate, what population, geography, year, case definition and ascertainment method apply? provenance
- Could care-access barriers or missing home-managed events explain apparent differences in recorded burden? boundary
Prevention, treatment and response Connects disease-specific care options with eligibility evidence, exposure, safety and outcomes.
Care depends on genotype, age, complications, treatment history and local guidance, and interventions change how disease state is interpreted.
Preventive and disease-modifying care
Tracks infection prevention, hydroxyurea and other therapies, and transfusion programmes with their indications.
Care indication and response
Link each intervention to a documented clinical purpose and relevant benefit and safety measures.
- Which preventive measures and disease-modifying treatments are documented, and what guideline or clinical indication supports each? provenance
- How have pain burden, acute chest events, anaemia and relevant safety measurements changed during the recorded exposure? measurement
- For transfusion exposure, are alloantibodies, reactions, iron burden and compatibility requirements available for clinical review? action
Potentially curative treatment state
Represents assessment and follow-up for haematopoietic stem-cell transplantation and gene therapy.
Eligibility and post-treatment outcome
Distinguish treatment candidacy, receipt, haematological response and persistent pre-existing injury.
- Which dated, jurisdiction-specific criteria and specialist assessment support candidacy for the particular transplantation or gene-therapy approach? action
- After treatment, what evidence establishes response, ongoing complications and required follow-up while preserving the original diagnostic history? measurement
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- This is recalled knowledge, not a researched or source-verified account; guideline currency and exact terminology should be checked.
- Confirm diagnostic interpretation against age, recent transfusion and treatment history; these can affect haemoglobin analysis.
- No prevalence estimate or universal measurement range is supplied because population, year, genotype, age and treatment materially affect them.
- Which of these check these first hold for the sense of sickle-cell disease this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- HbSS disease, commonly called sickle-cell anaemia
- HbSC disease
- HbS/β⁰-thalassaemia
- HbS/β⁺-thalassaemia
- HbS/D-Punjab disease
- HbS/O-Arab disease
- Which of these kinds and varieties hold for the sense of sickle-cell disease this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- WHO ICD-10 - D57 - Sickle-cell disorders category; includes sickle-cell trait, so this category alone does not establish disease. Subcodes depend on genotype, complications and national modification.
- HGNC gene symbol - HBB - Identifies the beta-globin gene, not the disease or a complete genotype.
- Traditional haemoglobin variant nomenclature - HbS; β6 Glu→Val - Describes the sickle haemoglobin substitution using mature beta-globin numbering; HGVS protein numbering includes the initiating methionine.
- SNOMED CT - Numeric concept identifiers - Distinguishes disease, genotypes and complications; an exact concept should be checked against the applicable edition.
- Which of these identifiers and schemes hold for the sense of sickle-cell disease this model covers, and on what evidence? provenance
Standards and regulation
Recalled without web access and unsourced; every item is a lead to verify.
- World Health Organization ICD classification: coding requires the applicable revision and national modification.
- National Heart, Lung, and Blood Institute: Evidence-Based Management of Sickle Cell Disease, Expert Panel Report, 2014.
- American Society of Hematology: 2020 guidelines for sickle-cell disease transfusion support.
- Which of these standards and regulation hold for the sense of sickle-cell disease this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Newborn screening followed by confirmatory haemoglobin analysis, with molecular testing where needed to resolve genotype.
- Genetic counselling that distinguishes affected individuals from carriers and explains reproductive inheritance.
- Longitudinal care addressing haemolysis, pain, infection prevention and organ complications.
- Disease-modifying treatment and assessment for potentially curative therapies in suitable patients.
- Registries and clinical studies that distinguish the underlying disease from individual complications and episodes of care.
- Which of these real-world use hold for the sense of sickle-cell disease this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Vaso-occlusive episodes can cause severe pain and tissue ischaemia.
- Acute chest syndrome can cause rapidly progressive respiratory compromise.
- Cerebral vasculopathy can cause overt stroke or silent cerebral infarction.
- Functional asplenia increases susceptibility to severe infection, particularly from encapsulated bacteria.
- Splenic sequestration, aplastic crises and chronic haemolysis can cause or worsen anaemia.
- Which of these failure modes and hazards hold for the sense of sickle-cell disease this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Disease burden is especially substantial in sub-Saharan Africa, with additional longstanding affected populations in India, the Middle East and Mediterranean regions; migration gives it worldwide distribution.
- Genotype frequencies and modifying genetic factors vary across populations, influencing clinical patterns without determining an individual's course.
- Access to newborn screening, preventive care, transfusion services and specialist treatment varies substantially between health systems.
- Which of these regional variation hold for the sense of sickle-cell disease this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Sickle-cell trait - Usually HbAS: one HbS allele and one normal beta-globin allele; carrier status is distinct from sickle-cell disease.
- Sickle-cell anaemia - A narrower term generally referring to HbSS disease; some clinical usage also groups HbS/β⁰-thalassaemia with it.
- Beta-thalassaemia - Defined by reduced or absent beta-globin production; it becomes a sickle-cell disease genotype when a beta-thalassaemia allele is inherited with HbS.
- Vaso-occlusive episode - An acute complication occurring in someone with the underlying disease, rather than the inherited condition itself.
- Sickle-cell disease diagnosis - The clinical assertion identifying the condition, supported by haemoglobin or genetic testing; the disease exists independently of when it is diagnosed.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of sickle-cell disease this model covers, and on what evidence? provenance
What the second pass must settle
- Which authoritative diagnostic sources and terminology conventions should govern subtype confirmation and the boundary of the term sickle-cell anaemia?
- What exact ICD-10 national modification, ICD-11 release and SNOMED CT edition mappings apply to the disease group, its genotypes and its complication states?
- Which age-, genotype- and jurisdiction-specific guidelines should supply surveillance schedules, escalation criteria and treatment eligibility?
- Which validated measures best capture home-managed pain, persistent pain, functional burden and organ progression without imposing an unsupported single severity stage?
- Which population- and year-specific epidemiological sources, and which long-term post-transplantation or gene-therapy evidence, are adequate for the intended deployment?